The relationship of laboratory values with prognosis in acute stroke recanalization treatment applied patients

Year 2023, Volume: 9 Issue: 5 - September 2023, 926 - 931, 04.09.2023

İbrahim Acır , Hacı Ali Erdoğan , Hülya Olgun Yazar , Melis Suskun , Vildan Yayla

https://doi.org/10.18621/eurj.1238144

Cited By: 1

Abstract

Objectives: Many factors affect the results of acute recanalization treatment and prognosis of ischemic stroke patients. Some markers which has a role in inflammation process cause atherosclerosis that leads to ischemic stroke. We aimed to evaluate the relationship between admission laboratory findings and prognosis in patients to whom acute recanalization therapy were applied.

Methods: In our study, we evaluated 139 acute stroke patients to whom acute recanalization therapies had been applied. Demographic data, glomerular filtration rate, uric acid, albumin, lipid profile, C-reactive protein, fibrinogen values were evaluated. Admission and discharge National Institutes of Health Stroke Scale and modified Rankin Scale scores were recorded. The effect of laboratory parameters on prognosis was examined. P <0.05 was considered significant.

Results: Tissue plasminogen activator therapy was applied to 53 (38.1%) patients, thrombectomy to 62 (44.6%) patients, tPA bolus+thrombectomy to 3 (2.2%) patients, tPA full dose+thrombectomy to 19 (13.7%), and thrombectomy+stent to 2 (1.4%) patients. None of the laboratory were statistically related to prognosis except for lymphocytes count (p = 0.012) and albumin (p = 0.01). There was no relationship between laboratory findings with hemorrhagic transformation and acute recanalization treatment outcome.

Conclusions: In the etiology of ischemic stroke, there are many inflammatory processes that cause atherosclerosis such as hypertension, hyperlipidemia, diabetes mellitus. The effect of admission laboratory values on prognosis has not been clarified. In patients with acute recanalization therapies, admission laboratory findings has no effect on patient management. Consequently, laboratory parameters provide limited information about the prognosis of patients who underwent acute recanalization therapies.

Keywords

Acute stroke, thrombectomy, thrombolysis in cerebral infarction (TICI), laboratory findings

References

• 1. Tamam Y. Iltumur K. Apak I. Assessment of acute phase proteins in acute ischemic stroke. Tohoku J Exp Med 2005;206:91-8.
• 2. Palasik W, Fiszer U, Lechowicz W, Czartoryska B, Krzesiewicz M, Lugowska A. Assessment of relations between clinical outcome of ischemic stroke and activity of inflammatory processes in the acute phase based on examination of selected parameters. Eur Neurol 2005;53:188-93.
• 3. Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, et al. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke 2003;34:e109-37.
• 4. Larrue V, von Kummer RR, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001;32:438-41.
• 5. Panç C, Güler A, Gürbak İ, Taşbulak Ö, Güner A, Kalkan AK, et al. Association between CRP/albumin ratio and long-term mortality in patients with chronIc limb-threatening ischemia undergoing endovascular therapy below the knee: the ACHILES-BTK Registry. Ann Vasc Surg 2022;82:172-80.
• 6. Samoilova EM, Yusubalieva GM, Belopasov VV, Ekusheva EV, Baklaushev VP. [Infections and inflammation in the development of stroke]. Zh Nevrol Psikhiatr Im S S Korsakova 2021;121:11-21. [Article in Russian]
• 7. McCabe JJ, O'Reilly E, Coveney S, Collins R, Healy L, McManus J, et al. Interleukin-6, C-reactive protein, fibrinogen, and risk of recurrence after ischaemic stroke: systematic review and meta-analysis. Eur Stroke J 2021;6:62-71.
• 8. Yildirim T, Kiris T, Avci E, Durusoy Yildirim SE, Argan O, Safak Ö, et al. Increased serum CRP-albumin ratio is independently associated with severity of carotid artery stenosis. Angiolgy 2020;71: 740-6.
• 9. Gaita L, Timar R, Lupascu N, Roman D, Albai A, Potre O, et al. The impact of hyperuricemia on cardiometabolic risk factors in patients with diabetes mellitus: a cross-sectional study. Diabetes Metab Syndr Obes 2019;12:2003-10.
• 10. Dong Y, Shi H, Chen X, Fu K, Li J, Chen H, et al. Serum uric acid and risk of stroke: a dose-response meta-analysis. J Clin Biochem Nutr 2021;68:221-7.
• 11. Tokgoz OS, Guney F, Kaya A, Bugrul A, Eruyar E, Buyukgol H, et al. Acute-phase stroke outcome and lipids. Sisli Etfal Hastan Tip Bul 2021;55:538-44.
• 12. Pikija S, Sztriha LK, Killer-Oberpfalzer M, Weymayr F, Hecker C, Ramesmayer C, et al. Contribution of serum lipid profiles to outcome after endovascular thrombectomy for anterior circulation ischemic stroke. Mol Neurobiol 2019;56:4582-8.